Pharmacodynamic Study of Vemurafenib in the Neoadjuvant Setting in Patients With Locally Advanced Thyroid Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 May 2019
Price : $35 *
At a glance
- Drugs Vemurafenib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 16 May 2019 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.
- 31 Aug 2018 Biomarkers information updated
- 17 Aug 2017 Status changed from recruiting to active, no longer recruiting.